Recent Pfizer Press Releases

  • 1/8/18 8:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the expiration and results of its previously announced (i) offer to purchase for cash (the “Tender Offer”) any and all of its outstanding €2,000,000,000 5.750 per cent. Notes due 2021 (the “2021 Notes”) from holders thereof, and related (ii) solicitation of consents (“Consents”) to amend the 2021 Notes and the indenture pursuant to which the 2021 Notes were issued (the “Indenture”) to shorten themore...
  • 1/8/18 8:00 am EST

    The Innovative Target Exploration Network (ITEN) aims to foster a novel collaborative relationship with select academic institutions and principal investigators in key hubs of scientific excellence

    The model is designed to identify academic research projects that have the potential to deliver innovative therapeutic targets and mechanisms of action within Pfizer’s core areas of expertise

    University of Cambridge, University of Oxford and University of Texas Southwestern are the first institutions to participate

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the creation of the Innovative Target Exploration Network (ITEN), a new, early-stage partnering model that enables collaborative relationships with select academic institutions and principal investigators around the world, to identify research projects that have the potential to deliver novel therapeutic targets and mechanisms of action to underpin future drug discovery in core areas of interest to Pfizermore...
  • 12/27/17 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 8:30 a.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registering for the webcast will bemore...
  • 12/21/17 6:35 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the pricing terms and the early tender results of its previously announced (i) offer to purchase for cash (the “Tender Offer”) any and all of its outstanding €2,000,000,000 5.750 per cent. Notes due 2021 (the “2021 Notes”) from holders thereof, and related (ii) solicitation of consents (“Consents”) to amend the 2021 Notes and the indenture pursuant to which the 2021 Notes were issued (the “more...
  • 12/19/17 4:11 pm EST

    Pfizer’s Third U.S. Hematology Approval in Five Months

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for BOSULIF® (bosutinib) to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). The sNDA was reviewed and approved under the FDA’s Priority Review and accelerated approval programs based on molecular andmore...
  • 12/19/17 11:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2017 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.more...
  • 12/18/17 11:44 am EST

    Board of Directors Approves Increase in Quarterly Cash Dividend to $0.34 Per Share and Authorizes New $10 Billion Share Repurchase Program

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 34-cent first-quarter 2018 dividend on the company’s common stock, payable March 1, 2018, to shareholders of record at the close of business on February 2, 2018. Pfizer increased the dividend by approximately 6 percent, to 34 cents from 32 cents per share. The first-quarter 2018 cash dividend will be the 317th consecutive quarterly dividend paid by Pfizer. Keeping with past practicemore...
  • 12/15/17 8:03 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the expiration and results of its previously announced offers to exchange and to repurchase any and all of its outstanding £1,500,000,000 6.500 per cent. Notes due 2038 (the “Old Notes”). Exchange Offer for 6.500 per cent. Notes due 2038 The first transaction consists of Pfizer’s private offer to exchange (the “Exchange Offer”) any and all of the Old Notes for newly issuedmore...
  • 12/14/17 7:26 pm EST

    XELJANZ/XELJANZ XR, the First Oral JAK Inhibitor in the U.S. for Adults with Moderate to Severe Rheumatoid Arthritis, is now Approved for Adults with Active Psoriatic Arthritis

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved XELJANZ® 5 mg twice daily (BID) and XELJANZ® XR (tofacitinib) extended release 11 mg once daily (QD) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). XELJANZ/XELJANZ XR is the first and onlymore...
  • 12/14/17 10:27 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced the pricing terms of its previously announced offers to exchange and to repurchase any and all of its outstanding £1,500,000,000 6.500 per cent. Notes due 2038 (the “Old Notes”). Exchange Offer for 6.500 per cent. Notes due 2038 The first transaction consists of Pfizer’s private offer to exchange (the “Exchange Offer”) any and all of the Old Notes for newly issued debtmore...